CGEM - Cullinan Therapeutics Inc
IEX Last Trade
19.6
0.740 3.776%
Share volume: 397,320
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$18.86
0.74
3.92%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
8.71%
1 Month
2.89%
3 Months
-14.00%
6 Months
8.41%
1 Year
79.98%
2 Year
55.06%
Key data
Stock price
$19.60
DAY RANGE
N/A - $19.70
52 WEEK RANGE
$7.64 - $30.19
52 WEEK CHANGE
$0.81
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/06/2024
Company detail
CEO: Nadim Ahmed
Region: US
Website: cullinanoncology.com
Employees: 73
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: cullinanoncology.com
Employees: 73
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
cullinan oncology is focused on investing in and developing a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. sourced from the cullinan dry lab as well as external collaborators, cullinan’s assets are managed by a single, highly experienced team of oncology professionals and drug developers across a lean, capital efficient operating model.
Recent news